Alzamend Neuro, Inc. (ALZN): Regulation FD Disclosure

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 &' CTRU Lithium is considered a gold-standard treatment for bipolar I disorder, and is also used therapeutically in major depressive disorder, schizophrenia, Alzheimer's disease, and post-traumatic stress disorder. However, its clinical utility is constrained by a na

Original reporting
Published Nov 18, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ALZN
Neutral
medium confidence
Mentioned
$ALZN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALZNNeutralLow
01

Why it matters

Because the excerpt highlights exploratory analyses and reports that no network-pair changes survived FDR correction, it is more consistent with incremental scientific communication than a decisive clinical readout.

02

Market read

Traders may update their view of AL001’s mechanistic/biomarker narrative, but the lack of statistically robust network-pair findings in the excerpt limits immediate re-rating catalysts.

03

What to watch

The excerpt emphasizes methodology and QC, but traders may focus on whether this Reg FD disclosure signals upcoming trial expansion, endpoint selection changes, or planned regulatory interactions not shown in the scraped text.

Relevance 4/10Novelty 4/10Timing: filed with the SEC on 2026-11-18, after-hours

Background

The 8-K is a Regulation FD disclosure (Item 7.01) that furnishes an exhibit describing AL001 versus lithium carbonate in a resting-state fMRI study in healthy participants.

Company-level read

Ticker impact

$ALZNNeutralMedium confidence
Context

Alzamend Neuro filed an 8-K Regulation FD disclosure describing its AL001 ionic lithium salicylate study design and exploratory fMRI findings versus lithium carbonate.

Expected impact

Likely limited near-term impact, with traders treating it as incremental clinical/scientific communication rather than a catalyst.

Evidence & confidence

The disclosure is framed around study methods and exploratory connectivity results, and the text states no network-pair changes survived FDR correction, reducing immediate signal strength.

Market effects

Adds incremental evidence on ionic lithium salicylate (AL001) neuroscience readouts, but does not clearly reset expectations for bipolar I or major depressive disorder programs.

None indicated.

None indicated.

Counterpoint

Even without FDR-surviving network-pair effects, the company may be using this as a platform to justify next-step studies or biomarker strategy, which could matter to longer-horizon biotech positioning.

Key entities

  • Alzamend Neuro, Inc.

    Subject of the SEC 8-K Regulation FD disclosure, discussing AL001 study design and exploratory fMRI connectivity results.

  • AL001

    Novel ionic lithium salicylate salt co-crystallized with L-proline, intended for improved brain delivery with less systemic exposure than inorganic lithium salts.

  • Lithium carbonate (Li2CO3)

    Standard-of-care inorganic lithium treatment used as the comparator in the described dosing and imaging protocol.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.